ScreenerHero

0IL8 Kyntra Bio, Inc.

LSE · GB · Healthcare · Biotechnology · kyntrabio.com
6.023USD+0.80%Mkt Cap: —P/E: —

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting C…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap—
Enterprise Value-45.08M USD
Revenue (TTM)4.62M USD
Gross Profit-22.57M USD
Net Income (TTM)-30.91M USD
Revenue/Share1.14 USD
Last Price6.023 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees34
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.90
EV/Revenue-9.77
P/S—
P/B-0.80
EPS (TTM)-3.04
EPS (Forward)—
52W Range
5.7204% of range12.60
52W High12.60 USD
52W Low5.720 USD
Profitability
Gross Margin0.00%
Oper. Margin1191.52%
EBITDA Margin0.00%
Profit Margin3968.63%
ROE—
ROA-22.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.05M USD
CapEx (TTM)—
FCF Margin1171.46%
FCF Yield—
Net Debt-91.32M USD
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity—
Current Ratio2.69
Quick Ratio2.54
Book Value/Sh-7.45 USD
Cash/Share22.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.04:1
Split DateJun 17, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.84.98M
Float3.57M
Insiders2.02%
Institutions24.68%
Technical
SMA 501.582 (+280.7%)
SMA 2002.791 (+115.8%)
Beta1.05
S&P 52W Chg15.78%
Avg Vol (30d)531
Avg Vol (10d)27.00K
Technical Indicators
RSI (14)29.4
MACD-0.3604
MACD Signal-0.2125
MACD Hist.-0.1479
BB Upper8.561 USD
BB Middle7.191 USD
BB Lower5.821 USD
BB Width38.11%
ATR (14)0.3716 USD
Vol Ratio (20d)2.32x